BBX Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function analysis of the BBX gene in the SK-HEP-1 hepatic adenocarcinoma background. This product provides a heterogeneous pool of cells harboring diverse mutations at the target locus, generated through non-homologous end joining-mediated gene disruption. As a polyclonal knockout, it avoids clonal bias and offers a population-level model for investigating BBX-dependent transcriptional and tumorigenic programs. The knockout is designed to abolish functional BBX protein expression, enabling researchers to dissect its roles in cell cycle regulation, Wnt signaling, and hepatic malignancy.
The host SK-HEP-1 cell line was originally derived from the ascitic fluid of a patient with liver adenocarcinoma and displays an endothelial-like phenotype alongside epithelial features. This dual character makes SK-HEP-1 particularly valuable for tumor microenvironment studies, as it partially recapitulates the vascular-like properties observed in hepatocellular carcinoma. The line is well-established in cancer biology for examining tumor?Cstroma interactions, angiogenesis, and metastatic potential, providing a unique platform to explore the intersection of endothelial and epithelial signaling networks.
BBX encodes an HMG-box transcription factor that functions as a critical node in cell cycle control and developmental gene regulation. Mechanistically, BBX is transcriptionally regulated by E2F transcription factors and is activated downstream of Wnt/??-catenin signaling. It forms complexes with LEF1, ??-catenin, and chromatin remodeling factors to modulate target gene expression. Among its transcriptional targets are MYC and CCND1, which encode key regulators of cell cycle progression, as well as other cell cycle regulators. Through these interactions, BBX coordinates proliferation signals, and its disruption is predicted to impair G1/S transition, dampen MYC-driven growth programs, and alter ??-catenin-dependent transcription.
In the SK-HEP-1 context, BBX knockout models the consequences of lost BBX activity within an endothelial-like hepatic adenocarcinoma environment. Given the cell line’s reliance on Wnt/??-catenin and E2F pathways??both of which are frequently dysregulated in hepatocellular carcinoma??ablation of BBX potentially attenuates tumorigenic properties such as proliferation, migration, and anchorage-independent growth. The polyclonal format reflects the spectrum of loss-of-function mutations, making it suitable for bulk assays that assess overall pathway responses, while also providing a more robust representation of genetic heterogeneity compared to single-cell clones. This model is particularly relevant for exploring how BBX influences the crosstalk between endothelial-like and epithelial-like characteristics in liver cancer.
This knockout cell product is ideally suited for a broad range of functional studies, including proliferation assays (MTT, BrdU), flow cytometric analysis of cell cycle and apoptosis, migration and invasion assays, as well as molecular readouts such as western blotting, RT-qPCR, and RNA-seq. For transcription factor target identification, ChIP-qPCR and reporter assays can be deployed to validate BBX binding sites and transcriptional activity. Researchers focused on hepatic tumor microenvironment dynamics, drug target validation, or Wnt/??-catenin and E2F pathway interrogation will find this model a powerful tool. For further technical details, please contact Ascent Research.
